TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for high risk and advanced cancers, announced the retirement of Chief Financial Officer Tom Fitzgerald, effective immediately. Fitzgerald, who has served as CFO since July 2018 and also served as a director, will continue to provide transition services to the company. The company has appointed John Tattory as interim CFO, also effective immediately.
The leadership transition comes at a critical time for TransCode, which is focused on developing innovative treatments for metastatic cancers. Fitzgerald's departure marks the end of a nearly six-year tenure during which the company advanced its lead therapeutic candidate, TTX-MC138, into clinical development. TTX-MC138 targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class candidates designed to mobilize the immune system against cancer cells.
John Tattory brings more than 25 years of financial and operational management experience across the pharmaceutical, medical device, and biotechnology sectors. His background includes roles at Ernst & Young LLP, Bristol-Myers Squibb, Tyco International, Cerapedics, and Windtree Therapeutics. Currently, he serves as a managing director at Stout Risius Ross, where he provides consulting CFO services primarily to privately held life science companies. Tattory's extensive experience in life sciences finance could be instrumental as TransCode navigates the complex financial landscape of clinical-stage drug development.
The appointment of an interim CFO may signal a period of transition for TransCode as it seeks a permanent finance leader. Investors will likely watch closely to see how Tattory's expertise influences the company's financial strategy, particularly regarding capital raising and investor communications. For a clinical-stage company like TransCode, which likely requires significant funding to advance its pipeline, having a seasoned financial leader is crucial. Tattory's background in both large pharmaceutical companies and smaller biotechs could provide valuable perspective as TransCode balances research and development investments with fiscal responsibility.
TransCode's mission to develop novel treatments for high-risk and advanced cancers remains unchanged. The company's focus on immuno-oncology and RNA therapeutics places it in a competitive and rapidly evolving field. With TTX-MC138 as its lead candidate, TransCode aims to address unmet needs in metastatic cancer treatment. The success of its clinical programs will depend not only on scientific breakthroughs but also on sound financial management, making the CFO role particularly important.
The full press release can be viewed at https://nnw.fm/8G3ik. For ongoing updates about TransCode Therapeutics, visit the company's newsroom at https://nnw.fm/RNAZ.
